So-called BACE drugs, biopharma’s next (and possibly doomed) hope for treating Alzheimer’s disease, have had a difficult run of form lately. First, two big trials from Merck came up short, and then another from Johnson & Johnson ran into damning safety problems.
And the latest data, on a BACE drug from Biogen, may only underline growing fears in Alzheimer’s research.
No matter how far you have gone on the wrong road, turn back.
— Turkish proverb
Comments are closed.